AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT00863369 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: bortezomib
Description: Given IV
Study NCT00863369 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: gemcitabine hydrochloride
Description: Given IV
Study NCT00863369 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: questionnaire administration
Description: Ancillary studies
Study NCT01754181 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Insulin
Description: the intervention is applied only at the dose of insulin
Study NCT03083054 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Autologous dendritic cells electroporated with WT1 mRNA
Description: Production and application of autologous dendritic cells vaccines, 4 doses, biweekly
Study NCT00299728 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: NY-ESO-1 Protein Vaccine
Description: NY-ESO-1 recombinant protein mixed with CpG 7909 and Montanide ISA-51 VG
Study NCT02748005 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Fenugreek seeds extract 500 mg
Description: one cap once a day
Study NCT02662322 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Hypnotic communication
Description: hypnotic communication during peripheral intravenous catheterization
Study NCT02662322 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: negative connotation communication
Description: negative connotation communication during peripheral intravenous catheterization
Study NCT02662322 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: neutral connotation communication
Description: neutral connotation communication during peripheral intravenous catheterization
Study NCT02662322 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: peripheral intravenous catheterization
Description: peripheral intravenous catheterization
Study NCT02662322 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: peripheral intravenous catheterization
Description: peripheral intravenous catheterization
Study NCT02662322 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: peripheral intravenous catheterization
Description: peripheral intravenous catheterization
Study NCT00654303 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rosuvastatin
Study NCT02048254 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: brachytherapy
Study NCT02048254 — intervention group
Intervention type: RADIATION
Group type: ACTIVE_COMPARATOR
Intervention: IMRT
Study NCT03406130 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Orthodontic Procedure
Description: Damon self-ligating systems (Ormco) were used for all patients. The patients were allowed to choose between clear and metal brackets. The bonding method was standardized and applied according to the manufacturer's instructions. After bracket bonding, 0.014-in. copper nickel-titanium Damon arch forms were placed. The subjects returned every 2 wk, and the archwires were changed only when full bracket engagement were achieved. The sequence of archwires was the following: 0.018-in., 0.014 × 0.025-in., and 0.018 × 0.025-in. copper nickel-titanium archwires were used for alignment, while 0.019 × 0.025-in. stainless-steel archwires were used for fine-tuning. Following the alignment steps, impressions were taken, and a blinded senior orthodontist validated appliance removal or provided advice regarding further adjustments.~Alginate impressions were taken after the removal of the appliances, and fixed and removable retainers were placed.
Study NCT03406130 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Orthodontic Procedure
Description: Damon self-ligating systems (Ormco) were used for all patients. The patients were allowed to choose between clear and metal brackets. The bonding method was standardized and applied according to the manufacturer's instructions. After bracket bonding, 0.014-in. copper nickel-titanium Damon arch forms were placed. The subjects returned every 2 wk, and the archwires were changed only when full bracket engagement were achieved. The sequence of archwires was the following: 0.018-in., 0.014 × 0.025-in., and 0.018 × 0.025-in. copper nickel-titanium archwires were used for alignment, while 0.019 × 0.025-in. stainless-steel archwires were used for fine-tuning. Following the alignment steps, impressions were taken, and a blinded senior orthodontist validated appliance removal or provided advice regarding further adjustments.~Alginate impressions were taken after the removal of the appliances, and fixed and removable retainers were placed.
Study NCT03406130 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Piezocision surgery
Description: The piezocision surgery was performed 1 week after orthodontic appliance placement. The surgical protocol was performed as described by Dibart and al. (Dibart et al. 2009). However, to avoid bias, hard and soft tissue augmentations were not considered. The patients received local anesthesia in both arches; vertical interproximal microincisions were created below each interdental papilla. In cases of root proximity (i.e., \<2 mm of interdental bone), this procedure was not performed. These incisions were kept to a minimum (varying from 5 to 8 mm). Next, with a vertical piezoelectric device, 5-mm-long and 3-mm-deep corticotomies were made, and no subsequent sutures were required. The patients were advised to take analgesics (paracetamol) only if necessary and to record their daily intake for 1 wk. Anti-inflammatories were prohibited to avoid interference with the RAP.
Study NCT02059733 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 18F-DTBZ
Description: During this study, subjects will receive a single i.v. administration of approximately 10 mCi 18F-DTBZ immediately prior to imaging.~The proposed dose for this study is based on our phase I study. At the proposed human dose of 10 mCi, the whole body effective dose (ED) will be approximately 680 mrem. The estimated human ED is expected to be comparable to or below the range of other approved brain imaging agents, such as 18F-FDG.
Study NCT00754195 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Thoracic epidural catheter
Description: Comparison of 3 insertion distances (3,5 and 7 cm) for a thoracic epidural catheter in the context of thoracic surgery.
Study NCT01955603 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: NNC0215-0384
Description: A total of seven once-weekly doses of NNC0215-0384 or placebo will be administered subcutaneously (s.c., under the skin) at one of three ascending dose levels. Each cohort will consist of eight subjects randomised to either active (6 subjects) or placebo (2 subjects) treatment. Each subject will participate in one cohort only. Dose-escalation to the next dose level will be initiated when the safety data has been evaluated and if considered safe.
Study NCT01955603 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: placebo
Description: Placebo administered corresponding to NNC0215-0384 treatment
Study NCT00382291 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Regular Titration
Description: Sertraline will be administered in standard dosing. Treatment with sertraline will last 18 weeks.
Study NCT00382291 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: The placebo will be administered in the same manner as sertraline. Treatment with placebo will last 18 weeks.
Study NCT04785404 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: primary skin closure
Description: skin will be stitched after stoma reversal to heal by primary intention
Study NCT00382291 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Slow Titration
Description: Sertraline will be administered in slow titration. Treatment with sertraline will last 18 weeks.
Study NCT02066389 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Tablets for oral administration
Study NCT02066389 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Upadacitinib
Description: Tablets for oral administration
Study NCT02884622 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: nasal epithelial
Description: CF patients with the same procedures as in the usual management of routine care, only the sampling nasal epithelial cells will be added
Study NCT02884622 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Blood sampling
Description: CF patients with the same procedures as in the usual management of routine care, only the sampling 5ml additional blood will be taken
Study NCT05494775 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Anti-vascular endothelial growth factors (Anti-VEGFs)
Description: Intravitreal injection of anti-vascular endothelial growth factors (Anti-VEGFs).
Study NCT00839800 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Symbicort Turbuhaler
Description: 160/4.5 µg
Study NCT00839800 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Symbicort Turbuhaler
Description: 160/4.5 µg
Study NCT00839800 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Terbutaline Turbuhaler
Description: 0.4 mg
Study NCT02502851 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Rotational Atherectomy
Description: Calcified lesion preparation using rotational atherectomy before implantation of the Orsiro drug eluting stent
Study NCT00450099 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: bupivacaine
Description: 0.125% bupivacaine in a volume determined according to the biased coin up-down sequential allocation model, starting at 8mL.
Study NCT03632928 — intervention group
Intervention type: OTHER
Intervention: Ultrasound Elastography
Description: Measuring muscle hardness at the trapezius and neck bilateral
Study NCT03632928 — intervention group
Intervention type: OTHER
Intervention: Pressure Pain threshold
Description: Measuring Pressure pain threshold at the trapezius and neck bilateral
Study NCT03503656 — intervention group
Intervention type: DEVICE
Intervention: epidural catheter placement
Description: insertion of an epidural catheter using Compuflo System
Study NCT03355222 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Promotion of chicken eggs
Description: Community is provided with chickens and young children are to receive one egg a day; selected mothers will consume eggshell.
Study NCT02502851 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Cutting/Scoring Balloon
Description: Calcified lesion preparation using cutting/scoring balloons before implantation of the Orsiro drug eluting stent
Study NCT03899844 — intervention group
Intervention type: OTHER
Intervention: Blood collection, PiB PET/MRI, and cognitive testing
Description: Blood and imaging results will be analyzed for amyloid beta. Cognitive testing will be performed to determine clinical and cognitive status.
Study NCT01456754 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: low feeding frequency (3x)
Description: 3 meals a day
Study NCT01456754 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: High feeding frequency (14x)
Description: 14 meals a day
Study NCT02081027 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Riluzole
Study NCT02081027 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Study NCT02116933 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Adipose Derived Stem Cells
Description: Adipose derived stem cells harvested from autologous lipoaspirate
Study NCT01200394 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PF-00489791
Description: Tablet, 20 mg once daily for 12 weeks
Study NCT01200394 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Tablet, placebo once daily for 12 weeks
Study NCT02784717 — intervention group
Intervention type: DRUG
Intervention: Rivaroxaban (Xarelto, BAY 59-7939)
Description: Decision regarding dose and duration of treatment made at the discretion of the attending investigator.
Study NCT01220011 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Fetoscopic laser surgery
Description: Fetoscopic laser surgery
Study NCT01220011 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Fetoscopic laser surgery
Description: Fetoscopic laser surgery
Study NCT03214497 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Protector
Description: All patients which are assigned to the Protector are studied with this laryngeal mask
Study NCT03214497 — intervention group
Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: Supreme
Description: All patients which are assigned to the Supreme are studied with this laryngeal mask
Study NCT02053350 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Alanyl-glutamine
Description: Alanyl-glutamine, 44g, taken by mouth daily for 10 days
Study NCT00392561 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Selenium
Description: 200 ug Selenium daily
Study NCT00392561 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: vitamin E
Description: 100 mg Vitamin E daily
Study NCT04109378 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Surgical procedures( conventional laparoscopic and NOSE technique) for the treatment of colorectal DIE
Description: For conventional laparoscopic and NOSE techniques a 4-port approach is used. The rectum is skeletonized. The distal rectum is closed using an endoscopic linear stapler. The mobilized rectum with the specimen is retrieved through a small suprapubic incision. The anvil of a conventional circular stapler is introduced in the proximal colon after placement of a purse string suture. A circular stapled colorectal anastomosis is fired. In case of NOSE, both the proximal sigmoid colon and the proximal rectum are tied off laparoscopically with a nonabsorbable suture. A transverse colotomy is performed in healthy tissue using a harmonic scalpel to deliver the anvil from a circular stapler introduced through the anus. The specimen is extracted transrectally in a specimen retrieval bag. Proximal part of the anastomosis is completed by suturing the anvil in place with a laparoscopic suture. The distal rectum is closed using a linear stapler. End-to-end anastomosis is made using the circular stapler
Study NCT03946943 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Anlotinib
Description: Once a day dosing of anlotinib alone for the first 7 days, Anlotinib ( 12mg, QD, PO, d1-14, 21 days per cycle), take once when limosis in the morning. If patients cannot suffer from AEs, they can get declined dosage.
Study NCT03946943 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Toripalimab
Description: Toripalimab 240mg shall be administered via intravenous (IV) infusion, once every 21 days, on day 8 and day 29 of the first cycle, and days 1 and 22 of the following cycles.
Study NCT01145703 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: RDA Vitamin D3 only
Description: 800 IU of Vitamin D3 daily for 6 months
Study NCT01145703 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Vitamin D2/3 Repletion only
Description: Vitamin D repletion with 50,000 IU of Vitamin D2/3 up to 3 x week(until levels are >75 nmol/l; 6-12wks) followed by 6 months maintenance supplementation with 2000 IU Vitamin D3 and up to 1000mg Calcium daily
Study NCT01145703 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Vitamin D2/3 Repletion + AEX
Description: Vitamin D repletion with 50,000 IU of Vitamin D2/3 up to 3 x week(until levels are >75 nmol/l; 6-12wks) followed by 6 months maintenance supplementation with 2000 IU Vitamin D3 and up to 1000mg Calcium daily plus aerobic exercise training
Study NCT01145703 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Vitamin D2/3 Repletion + RT
Description: Vitamin D repletion with 50,000 IU of Vitamin D2/3 up to 3 x week(until levels are >75 nmol/l; 6-12wks) followed by 6 months maintenance supplementation with 2000 IU Vitamin D3 and up to 1000mg Calcium daily plus resistance training
Study NCT03946943 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Blood Draw
Description: Peripheral blood draws for correlative studies characterizing T-cells in peripheral blood will be performed at three timepoints: 1) pre-treatment, 2) on-treatment on cycle 3 day 1, and 3) off-study.
Study NCT03946943 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Tumor Specimen Collection
Description: Tumor specimen collection via core needle biopsy for correlative studies characterizing T-cells in tumor tissue will occur at three timepoints: 1) pre-treatment, 2) on-treatment on cycle 3 day 1, and 3) off-study.
Study NCT01443962 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: PEEP
Description: applying PEEP 0 cmH2O during pneumoperitoneum continuously
Study NCT01443962 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: ZEEP
Description: applying PEEP 10 cmH2O during pneumoperitoneum continuously
Study NCT00698425 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: EyeGate II® Drug Delivery System
Description: Transscleral iontophoresis using citrate buffer delivered by EyeGate II® Drug Delivery System
Study NCT00698425 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Citrate buffer
Description: Transscleral iontophoresis using citrate buffer delivered by EyeGate II® Drug Delivery System
Study NCT03970720 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Metoclopramide
Description: 10 mg metoclopramide four times a day
Study NCT03970720 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: 10 mg matching placebo capsules four times a day
Study NCT00125931 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Talwin Nx
Description: Talwin NX 50mg po twice
Study NCT01941862 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Psychoeducation and Cognitive Bias Modification
Study NCT02359396 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MZRW
Description: MZRWs is composed of Fructus Cannabis (HuoMaRen), Radix et Rhizoma Rhei (DaHuang), Radix Paeoniae Alba (BaiShao), Semen Armeniacae Amarum (KuXingRen), Fructus Aurantii Immaturus (ZhiShi) and Cortex Magnoliae Officinalis (HouPo). All MZRW granules will be prepared by PuraPharm International (H.K.) Limited. The entire manufacturing process, from authenticating the raw materials to the final products, is in strict compliance with the standards of Good Manufactory Practice (GMP) and Chinese Pharmacopoeia.
Study NCT01739829 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: DIABECELL (R)
Description: 10,000 IEQ per kg body weight (Total Dose) Administered in two doses: 5,000 IEQ/kg three months apart.
Study NCT01739829 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: DIABECELL (R)
Description: 20,000 IEQ per kg body weight (Total Dose) Administered in two doses: 10,000 IEQ/kg three months apart
Study NCT04469179 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: SAB-185
Description: SAB-185 is a purified human immunoglobulin G (hIgG) designed to specifically bind to Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) viruses. SAB-185 is purified from the plasma of immunized Tc bovines that were immunized initially (vaccinations 1 and 2) with a plasmid DNA (pDNA) vaccine that expresses wild-type SARS-CoV-2 spike protein, followed by additional immunizations (vaccinations 3 and beyond) with a recombinant spike protein from SARS-CoV-2 produced in insect cells. The purified hIgG is a sterile liquid formulated in 10 mM glutamic acid monosodium salt, 262 mM D-sorbitol, 0.05 mg/mL Tween 80, pH 5.5. The drug product will be administered intravenously and will be diluted in saline per the clinical protocol.
Study NCT04469179 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Normal Saline
Description: Normal (0.9%) saline in approximately the same volume as each cohort in the experimental drug arm.
Study NCT02116933 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: SVF Enriched Autologous Fat Grafting
Description: Cell assisted lipotransfer
Study NCT04018131 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Cimetidine
Description: Antihistamine 2 antagonist
Study NCT03268031 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Visual field and OCT tests
Description: Visual field test and OCT are commonly used essential tests to make accurate diagnosis of glaucoma. Algorithms to classify Visual field and OCT tests would both be developed and verified.
Study NCT01427868 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LB80380 maleate salt
Description: 183 mg (150 mg as a free base)
Study NCT01427868 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: LB80380 free base
Description: 150 mg
Study NCT01490632 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Administered orally
Study NCT01490632 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Baricitinib
Description: Administered orally
Study NCT00522327 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: remote simultaneous medical interpreting
Description: remote simultaneous medical interpretation
Study NCT00522327 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: usual and customary
Description: usual and customary interpreting
Study NCT00522327 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: ENglish speaking
Description: English speakers